Eryka Karbowska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Eryka Karbowska has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandra Gąsecka
1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland
1 shared publication - Alla Navolokina
International European University
1 shared publication - Damian Swieczkowski
Department of Toxicology, Faculty of Pharmacy, Medical University of Gdańsk, Gdańsk, Poland
1 shared publication Fatemeh Shahabinejad
Kerman Medical University, Kerman, Iran
1 shared publication- Jerzy Robert Ładny
Department of Emergency Medicine, Medical University of Bialystok, 15-089 Bialystok, Poland
1 shared publication - Kamil Safiejko
Department of Oncological Surgery with Specialized Cancer Treatment Units, Maria Sklodowska-Curie Oncology Center, 15-027 Bialystok, Poland
1 shared publication
Latest Publications
- Open Access
- 26 April 2024
- Published by VM Media Group sp. z o.o in Cardiology Journal
- Vol. 31 (2) , 243-250
Statins and the risk of pancreatic cancer: A systematic review and meta-analysis of 2,797,186 patients
Background: Statin use in many studies is related to the improvement of a patients’ condition including reducing the risk of various malignancies. Herein, is a systematic review and meta-analysis to examine the evidence on the association between statin therapy and the risk of the occurrence of pancreatic cancer, mainly in terms of decreased risk of developing pancreatic cancer among patients using statin therapy in the long-term perspective. Methods: PubMed, Web of Science, Scopus and Cochrane Central Register of Controlled Trials (CENTRAL) were searched from database inception to December 1st, 2021. Random effect models were used to estimate summary odds ratios (OR) and the corresponding 95% confidence intervals (CI). Results: A total of 26 studies comprising 2,797,186 patients were included. Polled analysis showed that pancreatic cancer occurrence in statin vs. no-statin group varied and amounted to 0.4% vs. 0.6% (RR = 0.83; 95% CI: 0.72–0.96; I2 = 84%; p = 0.01). Conclusions: In summary, the present analysis shows that overall statins use is significantly associated with a reduction in risk of pancreatic cancer. However, these results were not confirmed for the randomized controlled trial subgroup. Further prospective studies are needed to confirm the current results. Background: Statin use in many studies is related to the improvement of a patients’ condition including reducing the risk of various malignancies. Herein, is a systematic review and meta-analysis to examine the evidence on the association between statin therapy and the risk of the occurrence of pancreatic cancer, mainly in terms of decreased risk of developing pancreatic cancer among patients using statin therapy in the long-term perspective. Methods: PubMed, Web of Science, Scopus and Cochrane Central Register of Controlled Trials (CENTRAL) were searched from database inception to December 1st, 2021. Random effect models were used to estimate summary odds ratios (OR) and the corresponding 95% confidence intervals (CI). Results: A total of 26 studies comprising 2,797,186 patients were included. Polled analysis showed that pancreatic cancer occurrence in statin vs. no-statin group varied and amounted to 0.4% vs. 0.6% (RR = 0.83; 95% CI: 0.72–0.96; I2 = 84%; p = 0.01). Conclusions: In summary, the present analysis shows that overall statins use is significantly associated with a reduction in risk of pancreatic cancer. However, these results were not confirmed for the randomized controlled trial subgroup. Further prospective studies are needed to confirm the current results.
- 26 April 2024
- Published by VM Media Group sp. z o.o in Cardiology Journal
- Vol. 31 (2) , 243-250
Open AccessStatins and the risk of pancreatic cancer: A systematic review and meta-analysis of 2,797,186 patients
Background: Statin use in many studies is related to the improvement of a patients’ condition including reducing the risk of various malignancies. Herein, is a systematic review and meta-analysis to examine the evidence on the association between statin therapy and the risk of the occurrence of pancreatic cancer, mainly in terms of decreased risk of developing pancreatic cancer among patients using statin therapy in the long-term perspective. Methods: PubMed, Web of Science, Scopus and Cochrane Central Register of Controlled Trials (CENTRAL) were searched from database inception to December 1st, 2021. Random effect models were used to estimate summary odds ratios (OR) and the corresponding 95% confidence intervals (CI). Results: A total of 26 studies comprising 2,797,186 patients were included. Polled analysis showed that pancreatic cancer occurrence in statin vs. no-statin group varied and amounted to 0.4% vs. 0.6% (RR = 0.83; 95% CI: 0.72–0.96; I2 = 84%; p = 0.01). Conclusions: In summary, the present analysis shows that overall statins use is significantly associated with a reduction in risk of pancreatic cancer. However, these results were not confirmed for the randomized controlled trial subgroup. Further prospective studies are needed to confirm the current results. Background: Statin use in many studies is related to the improvement of a patients’ condition including reducing the risk of various malignancies. Herein, is a systematic review and meta-analysis to examine the evidence on the association between statin therapy and the risk of the occurrence of pancreatic cancer, mainly in terms of decreased risk of developing pancreatic cancer among patients using statin therapy in the long-term perspective. Methods: PubMed, Web of Science, Scopus and Cochrane Central Register of Controlled Trials (CENTRAL) were searched from database inception to December 1st, 2021. Random effect models were used to estimate summary odds ratios (OR) and the corresponding 95% confidence intervals (CI). Results: A total of 26 studies comprising 2,797,186 patients were included. Polled analysis showed that pancreatic cancer occurrence in statin vs. no-statin group varied and amounted to 0.4% vs. 0.6% (RR = 0.83; 95% CI: 0.72–0.96; I2 = 84%; p = 0.01). Conclusions: In summary, the present analysis shows that overall statins use is significantly associated with a reduction in risk of pancreatic cancer. However, these results were not confirmed for the randomized controlled trial subgroup. Further prospective studies are needed to confirm the current results.
- Open Access
- 30 September 2022
- Published by VM Media Group sp. z o.o in Cardiology Journal
- Vol. 29 (5) , 886-887
Cardiac arrest outcomes in the COVID-19 era
- 30 September 2022
- Published by VM Media Group sp. z o.o in Cardiology Journal
- Vol. 29 (5) , 886-887
Open AccessCardiac arrest outcomes in the COVID-19 era